Positioning national sovereignty in animal health manufacturing
Get In TouchHealthy Animals .. Healthy People
Strengthening Saudi Arabia's food security through sovereign production and advancing national economic resilience. We are directly aligned with Vision 2030, the National Biotechnology Strategy, and Saudi Food Security Strategy.
Currently, 90% of animal vaccines are imported, creating critical vulnerability in national biosecurity and food supply chain. Local manufacturing accounts for less than 20% of production animal biologics in the GCC.
GCC population growth and changing diets mean 20-30% increase in protein demand by 2030. Surging livestock and poultry consumption necessitates secure, local vaccine supply.
2020-2024 disruptions caused 4 to 12-month shortages in critical poultry vaccines. Cold chain complexity increases wastage by 8-15% for imported biologics.
Local production can reduce vaccine costs by 15-40%. Import substitution in animal health can deliver SAR 750M-1.5B annual savings for Saudi Arabia's livestock economy.
Local production allows strain customization using local isolates, improving efficacy 10-30% versus generic global strains. Region faces recurrent outbreaks costing hundreds of millions annually.
Direct alignment with the Kingdom's strategic goals of localizing biotechnology manufacturing, enhancing food security, and diversifying the economy away from oil.
Designed for expansion with modular, single-use bioreactor systems for maximum flexibility, lower initial CAPEX, and rapid product changeover.
Partnering with leading global animal health company
One of the largest global animal health company with operations in 150+ countries.
KSA Presence: Poultry vaccines including IBD, Avian Influenza, Newcastle Disease, and Ruminant vaccines including FMD and Clostridial disease.
100% family-owned company with 50+ years in animal health and prevention, operating 40+ global subsidiaries.
BIOERA is a Saudi-based project management and consulting company headquartered in Riyadh, specializing in turnkey solutions for the biotechnology and pharmaceutical industries.
End-to-end project management for biopharmaceutical and life sciences facilities, from concept design to production.
Collaborates with leading international strategic partners to deliver advanced modular facility solutions.
Serves GCC region and extends services to MENA and Asia with proven track record.
Website: WWW.BIOERA.SA
First and only plant in KSA to produce biotechnology-derived products. Achieved "High level of compliance" rating and GMP certification from Novo Nordisk. Produced 17 million FlexPen devices in 2022.
State-of-the-art vaccines biomanufacturing facility with SAR 1,078M revenue projected by 2030. 42,000 m² facility in Sudair Industrial City with 11 vaccine products in portfolio.
Ready to discuss partnership opportunities or learn more about AniVax?
The Gate Centre, Othman bin Affan Rd
Office # 13-15, Riyadh, Saudi Arabia